Management of Hypertension in CKD: Beyond the Guidelines

  • Eric Judd
    Address correspondence to Eric Judd, MD, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, ZRB 510, 1530 3rd Avenue South, Birmingham, AL 35294-0007.
    Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
    Search for articles by this author
  • David A. Calhoun
    Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
    Search for articles by this author
      Hypertension (HTN) and CKD are closely associated with an intermingled cause and effect relationship. Blood pressure (BP) typically rises with declines in kidney function, and sustained elevations in BP hasten progression of kidney disease. This review addresses current management issues in HTN in patients with CKD including altered circadian rhythm of BP, timing of antihypertensive medication dosing, BP targets, diagnostic challenges in evaluating secondary forms of HTN, and the role of salt restriction in CKD. HTN in patients with CKD is often accompanied by a decrease in the kidney's ability to remove salt. Addressing this salt sensitivity is critical for the management of HTN in CKD. In addition to the well-established use of an ACEI or angiotensin receptor blocker, dietary salt restriction and appropriate diuretic therapy make up the mainstay of HTN treatment in patients with CKD. Bedtime dosing of antihypertensive medications can restore nocturnal dips in BP, and future clinical practice guidelines may recommend bedtime dosing of 1 or more antihypertensive medications in patients with CKD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bakris G.L.
        • Williams M.
        • Dworkin L.
        • et al.
        Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.
        Am J Kidney Dis. 2000; 36: 646-661
        • Lash J.P.
        • Go A.S.
        • Appel L.J.
        • et al.
        Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.
        Clin J Am Soc Nephrol. 2009; 4: 1302-1311
        • Egan B.M.
        • Zhao Y.
        • Axon R.N.
        US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.
        JAMA. 2010; 303: 2043-2050
        • Cai G.
        • Zheng Y.
        • Sun X.
        • Chen X.
        Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients With Hypertension in China.
        J Am Geriatr Soc. 2013; 61: 2160-2167
        • Tozawa M.
        • Iseki K.
        • Iseki C.
        • Kinjo K.
        • Ikemiya Y.
        • Takishita S.
        Blood pressure predicts risk of developing end-stage renal disease in men and women.
        Hypertension. 2003; 41: 1341-1345
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • et al.
        Blood pressure and end-stage renal disease in men.
        N Engl J Med. 1996; 334: 13-18
        • Parati G.
        • Stergiou G.
        • O'Brien E.
        • et al.
        European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.
        J Hypertens. 2014; 32: 1359-1366
        • Mancia G.
        • Fagard R.
        • Narkiewicz K.
        • et al.
        2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        Eur Heart J. 2013; 34: 2159-2219
        • Pogue V.
        • Rahman M.
        • Lipkowitz M.
        • et al.
        Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.
        Hypertension. 2009; 53: 20-27
        • Bangash F.
        • Agarwal R.
        Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis.
        Clin J Am Soc Nephrol. 2009; 4: 656-664
        • Cha R.H.
        • Kim S.
        • Ae Yoon S.
        • et al.
        Association between blood pressure and target organ damage in patients with chronic kidney disease and hypertension: results of the APrODiTe study.
        Hypertens Res. 2014; 37: 172-178
        • Minutolo R.
        • Gabbai F.B.
        • Agarwal R.
        • et al.
        Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study.
        Am J Kidney Dis. 2014; 64: 744-752
        • Boggia J.
        • Li Y.
        • Thijs L.
        • et al.
        Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study.
        Lancet. 2007; 370: 1219-1229
        • Liu M.
        • Takahashi H.
        • Morita Y.
        • et al.
        Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients.
        Nephrol Dial Transplant. 2003; 18: 563-569
        • Minutolo R.
        • Agarwal R.
        • Borrelli S.
        • et al.
        Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease.
        Arch Intern Med. 2011; 171: 1090-1098
      1. Haruhara K, Tsuboi N, Koike K, et al. Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients. [e-pub ahead of print, 2014 Sep 18.]. Hypertens Res. 2014.

        • Mojon A.
        • Ayala D.E.
        • Pineiro L.
        • et al.
        Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease.
        Chronobiol Int. 2013; 30: 145-158
        • Hermida R.C.
        • Smolensky M.H.
        • Ayala D.E.
        • et al.
        Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy.
        Nephrol Dial Transplant. 2014; 29: 1160-1167
        • Agarwal R.
        • Andersen M.J.
        Correlates of systolic hypertension in patients with chronic kidney disease.
        Hypertension. 2005; 46: 514-520
        • Higashi Y.
        • Oshima T.
        • Ozono R.
        • et al.
        Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-hour ambulatory blood pressure monitoring.
        Hypertension. 1997; 30: 163-167
        • Uzu T.
        • Sakaguchi M.
        • Yokomaku Y.
        • et al.
        Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
        Clin Exp Nephrol. 2009; 13: 300-306
        • Townsend R.R.
        • Wimmer N.J.
        • Chirinos J.A.
        • et al.
        Aortic PWV in chronic kidney disease: a CRIC ancillary study.
        Am J Hypertens. 2010; 23: 282-289
        • Gates P.E.
        • Tanaka H.
        • Hiatt W.R.
        • Seals D.R.
        Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension.
        Hypertension. 2004; 44: 35-41
        • Logan A.G.
        • Perlikowski S.M.
        • Mente A.
        • et al.
        High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.
        J Hypertens. 2001; 19: 2271-2277
        • Sakaguchi Y.
        • Shoji T.
        • Kawabata H.
        • et al.
        High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study.
        Clin J Am Soc Nephrol. 2011; 6: 995-1000
        • Langstan J.B.
        • Guyton A.C.
        • Douglas B.H.
        • Dorsett P.E.
        • Russel A.
        • McCaa R.E.
        Effect of changes in salt intake on arterial pressure and renal function in partially nephrectomized dogs.
        Circ Res. 1963; 12: 508-513
        • Guyton A.C.
        Blood pressure control—special role of the kidneys and body fluids.
        Science. 1991; 252: 1813-1816
        • Ying W.Z.
        • Sanders P.W.
        Dietary salt modulates renal production of transforming growth factor-beta in rats.
        Am J Physiol. 1998; 274: F635-F641
        • Fellner R.C.
        • Cook A.K.
        • O'Connor P.M.
        • Zhang S.
        • Pollock D.M.
        • Inscho E.W.
        High-salt diet blunts renal autoregulation by a reactive oxygen species-dependent mechanism.
        Am J Physiol Renal Physiol. 2014; 307: F33-F40
        • Smyth A.
        • O'Donnell M.J.
        • Yusuf S.
        • et al.
        Sodium intake and renal outcomes: a systematic review.
        Am J Hypertens. 2014; 27: 1277-1284
        • American Diabetes Associations
        Standards of medical care in diabetes—2013.
        Diabetes Care. 2013; 36: S11-S66
      2. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.
        J Hypertens. 2013; 31: 1925-1938
        • Go A.S.
        • Bauman M.A.
        • Coleman King S.M.
        • et al.
        An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention.
        Hypertension. 2014; 63: 878-885
        • Group KDIGOKBPW
        Clinical practice guideline for the evaluation and management of blood pressure in chronic kidney disease.
        Kidney Int Suppl. 2012; 2: 337-414
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • et al.
        2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 311: 507-520
        • Krause T.
        • Lovibond K.
        • Caulfield M.
        • McCormack T.
        • Williams B.
        Management of hypertension: summary of NICE guidance.
        BMJ. 2011; 343: d4891
        • Weber M.A.
        • Schiffrin E.L.
        • White W.B.
        • et al.
        Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension.
        J Clin Hypertens (Greenwich). 2014; 16: 14-26
        • Taler S.J.
        • Agarwal R.
        • Bakris G.L.
        • et al.
        KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.
        Am J Kidney Dis. 2013; 62: 201-213
        • Upadhyay A.
        • Earley A.
        • Haynes S.M.
        • Uhlig K.
        Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.
        Ann Intern Med. 2011; 154: 541-548
        • Kovesdy C.P.
        • Bleyer A.J.
        • Molnar M.Z.
        • et al.
        Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.
        Ann Intern Med. 2013; 159: 233-242
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Hypertension. 2008; 51: 1403-1419
        • Bax L.
        • Woittiez A.J.
        • Kouwenberg H.J.
        • et al.
        Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
        Ann Intern Med. 2009; 150 (w150-w841): 840-848
        • Wheatley K.
        • Ives N.
        • Gray R.
        • et al.
        Revascularization versus medical therapy for renal-artery stenosis.
        N Engl J Med. 2009; 361: 1953-1962
        • Cooper C.J.
        • Murphy T.P.
        • Cutlip D.E.
        • et al.
        Stenting and medical therapy for atherosclerotic renal-artery stenosis.
        N Engl J Med. 2014; 370: 13-22
        • McMahon E.J.
        • Bauer J.D.
        • Hawley C.M.
        • et al.
        A randomized trial of dietary sodium restriction in CKD.
        J Am Soc Nephrol. 2013; 24: 2096-2103
        • Slagman M.C.
        • Waanders F.
        • Hemmelder M.H.
        • et al.
        Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
        BMJ. 2011; 343: d4366
        • Vogt L.
        • Waanders F.
        • Boomsma F.
        • de Zeeuw D.
        • Navis G.
        Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
        J Am Soc Nephrol. 2008; 19: 999-1007
        • Institute of Medicine
        Sodium Intake in Populations: Assessment of Evidence.
        The National Academies Press, Washington, DC2013
        • Anderson C.A.
        • Ix J.H.
        Sodium reduction in CKD: suggestively hazardous or intuitively advantageous?.
        J Am Soc Nephrol. 2013; 24: 1931-1933
        • Agarwal R.
        • Sinha A.D.
        Thiazide diuretics in advanced chronic kidney disease.
        J Am Soc Hypertens. 2012; 6: 299-308
        • Dussol B.
        • Moussi-Frances J.
        • Morange S.
        • Somma-Delpero C.
        • Mundler O.
        • Berland Y.
        A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease.
        J Clin Hypertens (Greenwich). 2012; 14: 32-37
        • Carter B.L.
        • Ernst M.E.
        • Cohen J.D.
        Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
        Hypertension. 2004; 43: 4-9
        • Crespo J.J.
        • Pineiro L.
        • Otero A.
        • et al.
        Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease.
        Chronobiol Int. 2013; 30: 159-175
        • Hermida R.C.
        • Ayala D.E.
        Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing.
        Hypertension. 2009; 54: 40-46
        • Hermida R.C.
        • Ayala D.E.
        • Mojon A.
        • Fernandez J.R.
        Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
        Chronobiol Int. 2010; 27: 1629-1651
        • Hermida R.C.
        • Ayala D.E.
        • Mojon A.
        • Fernandez J.R.
        Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD.
        J Am Soc Nephrol. 2011; 22: 2313-2321
        • Hermida R.C.
        • Ayala D.E.
        • Mojon A.
        • Fernandez J.R.
        Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes.
        Diabetes Care. 2011; 34: 1270-1276
        • Chapman N.
        • Dobson J.
        • Wilson S.
        • et al.
        Effect of spironolactone on blood pressure in subjects with resistant hypertension.
        Hypertension. 2007; 49: 839-845
        • Vaclavik J.
        • Sedlak R.
        • Plachy M.
        • et al.
        Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
        Hypertension. 2011; 57: 1069-1075
        • Pisoni R.
        • Acelajado M.C.
        • Cartmill F.R.
        • et al.
        Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
        J Hum Hypertens. 2012; 26: 502-506
        • Shavit L.
        • Lifschitz M.D.
        • Epstein M.
        Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
        Kidney Int. 2012; 81: 955-968
        • Judd E.
        • Calhoun D.A.
        Apparent and true resistant hypertension: definition, prevalence and outcomes.
        J Hum Hypertens. 2014; 28: 463-468